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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S483the medial femur (-64%), not at other surfaces and not in the total joint
score (-16%).
Then, we treated collagenase-induced OA (CIOA) with paquinimod and
evaluated the effects on day 42. In CIOA, synovial activation is high and
S100A8/A9 levels in the synovium are signiﬁcantly higher than those in
DMM. Synovial activation was signiﬁcantly reduced by paquinimod-
treatment at the medial side of the patella-femur region (-57%).
Osteophyte size was signiﬁcantly reduced at the medial femur (-66%)
and cruciate ligaments (-67%). Finally, OA-like cartilage pathology in
CIOA was signiﬁcantly reduced after paquinimod treatment on the
medial side of both tibia and femur (-47% and -75% respectively) as well
as in the total joint score (-46%) (Figure 1).
Conclusions: Paquinimod administered in the drinking water reduces
synovial activation, osteophyte formation and OA-like cartilage path-
ology in CIOA. In contrast, in an experimental OA model where synovial
activation is nearly absent (DMM), the effect of paquinimod is marginal.
Paquinimod could prove a very promising treatment for osteoarthritis
patients with high synovial activation by blocking S100A9.
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A FUSION PROTEIN OF IL4 AND IL10 (IL4-10 SYNERKINE), IS VERY
EFFECTIVE IN PROTECTING CARTILAGE FROM BLOOD-INDUCED
DAMAGE
L.F. van Vulpen, M.E. van Meegeren, C. Steen-Louws, C.E. Hack,
S.C. Mastbergen, F.P. Lafeber. UMC Utrecht, Utrecht, Netherlands
Purpose: Interleukin 4 (IL4), IL10 or the combination of both protects
cartilage from blood-induced damage in vitro. Because IL4 and IL10 use
different signaling pathways they are able to exert different, but also
potentially additive effects. It has been postulated that they can act in
synergy enhancing their beneﬁcial effects and controlling their indi-
vidual adverse effects. Therefore a combination of IL4 and IL10 might be
the best option to administer in vivo.
To overcome the low bioavailability of IL4 and IL10 in vivo, a fusion
protein has been developed: IL4-10 synerkine. It has been demon-
strated that this novel drug inhibits numerous pro-inﬂammatory
cytokines secreted by monocytes and T-cells. This study investigates
whether this IL4-10 synerkine protects against blood-induced cartilage
damage similarly as the combination of the individual components.
Methods: Human cartilage explants were exposed to 50% v/v whole
blood for 4 days and simultaneously to a broad concentration range (0-
100 ng/mL) of the IL4-10 synerkine. Effects of 10 ng/mL IL4-10 syn-
erkine were compared to the same concentrations of the individual
cytokines and the combination. Cartilage matrix proteoglycan turnover
was assessed after a recovery period of 12 days. Moreover, the inﬂuence
of IL4-10 synerkine (10 ng/mL) and its individual components on levels
of IL1b and IL6 were investigated in a 4 days 50% v/v whole blood
culture.
Results: Exposure to 50% v/v whole blood resulted in a clear statistical
signiﬁcant decrease of proteoglycan (PG) synthesis rate (-74%; p ¼
0.012) and an increase of PG release (þ92%, p ¼ 0.017) compared toFigure – Effect of the IL4-10 synerkine compared to 1L4. IL10 and the
combination of both cytokines (all 10ng/mL) on cartilage proteoglycan
synthesis rate (A) and release (B) (n¼8 individual donors). Median values
 interquartile range are depicted. Hash tags indicate a statistically sig-
niﬁcant difference compared to 50% v/v blood (p<0.05). asterisks indicate
a statistically signiﬁcant difference compared to control cartilage
(p<0.05).control. Adding of IL4-10 synerkine, resulted in a clear dose-response
curve, leading to full normalisation of PG synthesis rate and -release at
higher concentrations (>10 ng/mL). These results were similar to the
effect of the two individual cytokines combined (see ﬁgure). The indi-
vidual cytokines had amore distinct proﬁle where IL4 was superior over
IL10 (see ﬁgure). Moreover, addition of IL4-10 synerkine reduced IL1b
and IL6 production in whole blood cultures to control levels (both p <
0.05), similar to the combination of IL4 plus IL10 (p ¼ 0.180 and p ¼
0.173, respectively).
Conclusions: IL4-10 synerkine strongly protects against blood-induced
cartilage damage in vitro, presumably at least in part by reduction of
pro-inﬂammatory cytokines including IL1b and IL6. Considering better
bioavailability and more easy application of this synerkine compared to
the individual cytokines, testing the IL4-10 synerkine in an in vivo
model of blood-induced cartilage damage is warranted.
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Purpose: Aggrecanase activity, most notably ADAMTS-5, has been
widely implicated as a pathogenic factor in cartilage degradation.
Therefore, highly selective and potent monoclonal antibodies (mAbs) to
both ADAMTS-5 and ADAMTS-4 were developed and experimental
systems were utilized to assess target engagement and modulation of
disease-related and safety endpoints with the intent of selecting a
candidate and supporting clinical development in osteoarthritis (OA).
Methods/Results: In a surgical mouse model of OA, both ADAMTS-5
and ADAMTS-4-speciﬁc mAbs bound within cartilage following sys-
temic administration, demonstrating access to the anticipated site of
action, whereas structural disease modiﬁcation and associated allevia-
tion of pain-related behavior were only observed with ADAMTS-5 mAb
treatment. Likewise, ex vivo treatment of human OA cartilage demon-
strated a preferential role for ADAMTS-5 inhibition over ADAMTS-4, as
measured by aggrecan-derived 374ARGS neoepitope release in explant
cultures and was most evident in a distinct subset of patients where
elevated 374ARGS neoepitope levels were present in explants prior to
treatment. Notably, suppression of 374ARGS neoepitope release was
sustained for weeks after a single treatment of human cartilage explants
and in cynomolgus monkeys, consistent with a high afﬁnity antibody/
antigen interaction and slowADAMTS-5 turnover that could translate to
less frequent clinical dosing. As a result an ADAMTS-5 selective mon-
oclonal antibody (GSK2394002) was progressed for preclinical devel-
opment as a potential OA disease modifying therapeutic.
While desired pharmacology was observed in explant cartilage and
disease models, ADAMTS-5 is also expressed in cardiovascular (CV)
tissue. Recently it was reported that knockout mice show devel-
opmental heart valve defects and altered vascular and ﬁbroblast pro-
teoglycan processing. Along with these observations, an initial
histologic cardiac signal in cynomolgus monkeys (subendocardial
hemorrhage) prompted a careful assessment of CV function in a set of
dedicated safety pharmacology studies. In these studies, increased
mean arterial pressure (MAP) was observed within days after>3 mg/kg
dosing and ST segment elevation was noted on 24 hour continuous ECG
monitoring>30mg/kg. Surprisingly, these effects were sustained for up
to 8 months following a single dose and MAP was increased upon
repeated low dose administration suggesting the effects are cumulative
and, unlike the systemic pharmacodynamic marker signal, once
induced they may not be readily reversible. Although a potential
mechanistic link between ADAMTS-5 activity and versican processing is
demonstrated, the cause of these cardiovascular observations is cur-
rently unknown. In a parallel general toxicology study, there were no
histologic or biochemical correlates to the CV ﬁndings and no evidence
of off-target mechanisms could be identiﬁed using in vitro tests
examining cardiac conductance, ion channels, or binding selectivity in
protein arrays.
Conclusions: The ﬁndings support a hypothesis set forth from knockout
mouse studies that ADAMTS-5 is the major aggrecanase involved in
Figure 1. Anti-inﬂammatory cytokine concentrations.* signiﬁcantly < APS
Device System (p<0.05, t-test).
Figure 2. Anabolic growth factor concentrations.* signiﬁcantly < APS
Device System (p< 0.05, t-test).
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S484cartilage degradation and conﬁrms a link between a native biological
pathway and pharmacology which translates to human tissues and
non-human primate models, subsequently pointing to a speciﬁc OA
patient population to target. However, our results suggest selective and
potent ADAMTS-5 engagement/inhibition with GSK2394002, while
demonstrating desired effects on cartilage-related endpoints, results in
modulation of CV functions that pose considerable challenges for clin-
ical development.
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COMPARISON OF THE CELLULAR AND CYTOKINE CONCENTRATIONS
IN THE OUTPUT OF THE AUTOLOGOUS PROTEIN SOLUTION,
ORTHOKINE, AND ONOCCOMED 2 DEVICE SYSTEMS
W. King, J. Woodell-May. Biomet, Warsaw, IN, USA
Purpose: The purpose of this study was to characterize the cellular and
cytokine concentrations in the outputs of the Autologous Protein Sol-
ution (APS), Orthokine, and Onoccomed 2 Device Systems. Anti-
inﬂammatory cytokines and anabolic growth factors were analyzed due
to their potential role in inhibiting damaging inﬂammation in osteo-
arthritis (OA) and inducing disease-modifying cartilage repair.
Methods: Blood from 6 human donors (WIRB Study # 1115097) was
drawn and allocated so that blood from each donor was used for 1)
whole blood analysis, 2) processing with the APS Device System (Bio-
met, Warsaw, IN, USA), 3) Orthokine Device System (Orthogen Lab
Services, Dusseldorf, Germany), and the Onoccomed 2 Device System
(Plasmaconcept AG, Bonn, Germany). Each device systemwas processed
according to the manufacturer’s instructions. Cellular content was
analyzed using a Cell Dyn 3700 hematology analyzer (Abbott Labo-
ratories, Chicago, IL, USA). Cytokine content was measured using
enzyme-linked immunosorbent assays (R&D Systems, Minneapolis,
MN, USA).
Results: The APS Device System produced a solution with greater
concentrations of white blood cells (WBC) and platelets (PLT) than
whole blood, the output of the Orthokine Device System, and the
Onoccomed 2 Device System (p < 0.05, t-test). The output of the APS
Device System contained signiﬁcantly decreased red blood cell (RBC)
concentrations than whole blood, but greater than the RBC concen-
trations in the conditioned serums produced by the Orthokine and
Onoccomed 2 Device Systems (p < 0.05, t-test) (Table 1).
The APS Device System produced solutions with signiﬁcantly greater
concentrations of anti-inﬂammatory cytokines than the Orthokine and
Onoccomed 2 device systems (Figure 1). For example, the concentration
of interleukin-1 receptor antagonist (IL-1ra) in the output of the APS
device system was 54,922.1  32,750.7 (pg/ml), whereas the output of
the Orthokine device systemwas 1,618.0 674.7 (pg/ml) and the output
of the Onoccomed 2 device system was 277.1  338.2 (pg/ml). The
concentration of IL-1ra in the outputs of the Orthokine and Onoccomed
2 device systems were signiﬁcantly less than the IL-1ra concentration in
whole blood (5664.5  2,317.6 pg/ml) (p < 0.05). The output of the APS
device system also contained signiﬁcantly greater concentrations of
soluble interleukin-1 receptor antagonist type II (sIL-1RII), soluble
tumor necrosis factor type I (sTNF-RI), and sTNFR-II (p < 0.05, t-test)
(Figure 1).
The APS Device System produced solutions with similar or signiﬁcantly
greater concentrations of anabolic growth factors compared to the
other device systems. For example, the APS Device System produced a
solution that contained 13,575.9  5,959.2 (pg/ml) platelet-derived
growth factor-BB (PDGF-BB). The Onoccomed 2 and Orthokine device
systems had outputs containing 2,302.3  1,022.6 and 2,765.5  1,101.2
(pg/ml) PDGF-BB, respectively (p < 0.05, t-test). The APS Device System
also produced solutions with signiﬁcantly greater concentrations of
PDGF-AB, transforming growth factor-b (TGF-b), and epidermal growth
factor (EGF) compared to the Onoccomed 2 Device System (p < 0.05, t-Table 1
Concentration of white blood cells (WBC) (k/ml), Platelets (k/ml), and red blood cells
(RBC) (M/ml)
WBC (k/ml) PLT (k/ml) RBC (M/ml)
Whole blood 5.4  1.8 175.1  69.5 5.5  1.1
APS 46.5  19.9 1184.4  556.4 1.4  1.5
Orthokine 0.0  0.0 13.5  5.5 0.0  0.0
Onoccomed 2 0.0  0.0 11.4  1.7 0.0  0.0test). There were no signiﬁcant differences in the concentrations of EGF,
insulin-like growth factor-1 (IGF-1), and TGF-b in the outputs of the APS
and Orthokine device systems. However, the APS Device System pro-
duced solutions with signiﬁcantly greater concentrations of PDGF-AB
and PDGF-BB than the Orthokine Device System (p < 0.05, t-test).
Conclusions: The APS device system produced solutions with sig-
niﬁcantly greater concentrations of anti-inﬂammatory cytokines and
similar or greater concentrations of anabolic growth factors than the
Orthokine or Onoccomed 2 Device Systems. Signiﬁcantly, the average
IL-1ra concentration in the output of the APS Device system was 34X
that of the Orthokine Device System and 198X that of the Onoccomed 2
Device System from the same donors. The cytokine proﬁle of APS can be
attributed to its increased concentrations of WBC and platelets com-
pared to the acellular conditioned serums.
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